Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis by Tardelli, Matteo et al.
  
 University of Groningen
Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing
Cholangitis
Tardelli, Matteo; Bruschi, Francesca V; Fuchs, Claudia D; Claudel, Thierry; Auer, Nicole;






IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2019
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Tardelli, M., Bruschi, F. V., Fuchs, C. D., Claudel, T., Auer, N., Kunczer, V., ... Trauner, M. (2019).
Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Hepatology. https://doi.org/10.1002/hep.30929
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 21-02-2020
1Hepatology, Vol. 0, No. 0, 2019 
Monoacylglycerol Lipase Inhibition 
Protects From Liver Injury in Mouse 
Models of Sclerosing Cholangitis
Matteo Tardelli,1 Francesca V. Bruschi ,1 Claudia D. Fuchs,1 Thierry Claudel,1 Nicole Auer,1 Victoria Kunczer,1 
Maximilian Baumgartner,2 Onne A.H.O. Ronda,3 Henk Jan Verkade,3 Tatjana Stojakovic,4 Hubert Scharnagl,5 Aida Habib ,6,7 
Robert Zimmermann,8 Sophie Lotersztajn,6 and Michael Trauner1
BaCKgRoUND aND aIMS: Monoacylglycerol lipase 
(MGL) is the last enzymatic step in triglyceride degradation, 
hydrolyzing monoglycerides into glycerol and fatty acids (FAs) 
and converting 2-arachidonoylglycerol into arachidonic acid, 
thus providing ligands for nuclear receptors as key regulators 
of hepatic bile acid (BA)/lipid metabolism and inflammation. 
We aimed to explore the role of MGL in the development 
of cholestatic liver and bile duct injury in mouse models of 
sclerosing cholangitis, a disease so far lacking effective phar-
macological therapy.
appRoaCH aND ReSUltS: To this aim we ana-
lyzed the effects of 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
(DDC) feeding to induce sclerosing cholangitis in wild-type 
(WT) and knockout (MGL−/−) mice and tested pharmaco-
logical inhibition with JZL184 in the multidrug resistance 
protein 2 knockout (Mdr2−/−) mouse model of sclerosing 
cholangitis. Cholestatic liver injury and fibrosis were as-
sessed by serum biochemistry, liver histology, gene expression, 
and western blot characterization of BA and FA synthesis/ 
transport. Moreover, intestinal FAs and fecal microbiome were 
analyzed. Transfection and silencing were performed in Caco2 
cells. MGL−/− mice were protected from DDC-induced biliary 
fibrosis and inflammation with reduced serum liver enzymes 
and increased FA/BA metabolism and β-oxidation. Notably, 
pharmacological ( JZL184) inhibition of MGL ameliorated 
cholestatic injury in DDC-fed WT mice and protected 
Mdr2−/− mice from spontaneous liver injury, with improved 
liver enzymes, inflammation, and biliary fibrosis. In vitro ex-
periments confirmed that silencing of MGL decreases pros-
taglandin E2 accumulation in the intestine and up-regulates 
peroxisome proliferator–activated receptors alpha and gamma 
activity, thus reducing inflammation.
CoNClUSIoNS: Collectively, our study unravels MGL as 
a metabolic target, demonstrating that MGL inhibition may 
be considered as potential therapy for sclerosing cholangitis. 
(Hepatology 2019;0:1-16).
Cholangiopathies such as primary sclerosing cholangitis (PSC) and primary biliary chol-angitis (PBC) are chronic hepatobiliary dis-
orders characterized by accumulation of bile acids 
(BAs) in the liver, leading to hepatocellular necrosis, 
progressive fibrosis, and end-stage liver disease.(1,2) 
Current therapeutic approaches for treating cholesta-
sis mainly rely on the use of ursodeoxycholic acid 
(UDCA) as first-line treatment; however, UDCA has 
no proven efficacy for PSC, and only a proportion 
of patients with PBC show a sufficient response.(3) 
Monoacylglycerol lipase (MGL) is the rate-limiting 
enzyme in the degradation of monoacylglycerols.(4) 
MGL hydrolyzes monoacylglycerols deriving from 
Abbreviations: AA, arachidonic acid; Abhd6/Abhd12, α/β hydrolase domains 6 and 12; 2-AG, 2-arachidonoylglycerol; ALT, alanine aminotransferase; 
Aox, acyl-coenzyme A oxidase; AP, alkaline phosphatase; AST, aspartate aminotransferase; ATP, adenosine triphosphate; BA, bile acid; BEC, biliary 
epithelial cell; Bsep, bile salt export pump; CD, cluster of differentiation; CDCA, chenodeoxycholic acid; Ck19, cytokeratin 19; Col1α1/Col1α2, collagen 
types 1α 1 and 2; Cox2, cyclooxygenase-2; Cpt1α, carnitine palmitoyltransferase 1A; Cyp7a1, cytochrome P450 7A1; DDC, 3,5-diethoxycarbonyl-1,4-
dihydrocollidine; DMEM, Dulbecco’s modif ied Eagle’s medium; FA, fatty acid; FBS, fetal bovine serum; Fgf, f ibroblast growth factor; FXR, farnesoid 
X receptor; FXRE, FXR response element; h, human; H&E, hematoxylin and eosin; Hmox1/HO-1, heme oxygenase 1; IHC, immunohistochemistry; 
IHH, immortalized human hepatocyte; LPS, lipopolysaccharide; Mac-2, galectin-3; Mcp1, monocyte chemoattractant protein 1; Mdr2, multidrug 
resistance protein 2; MGL, monoacylglycerol lipase; Mrp2/3/4, adenosine triphosphate binding cassette subfamily C member 2/3/4; NR, nuclear 
receptor; Nrf2, nuclear factor erythroid 2–related factor 2; Ntcp, sodium-taurocholate cotransporting polypeptide; Oatp1, ornithine aminotransferase 
pseudogene 1; Opn, osteopontin; PBC, primary biliary cholangitis; Pgc1α, peroxisome proliferator–activated receptor-gamma coactivator 1 alpha; PGE2, 
prostaglandin E2; PG-G, prostaglandin glycerol ester; Ppar, peroxisome proliferator–activated receptor; PSC, primary sclerosing cholangitis; RXR, 
retinoid X receptor; si, small interfering; Srebp1c/Srebp2, sterol regulatory element-binding proteins 1c and 2; TG, triglycerides; Tgfβ, transforming 
growth factor beta; Tnfα, tumor necrosis factor alpha; Vcam-1, vascular cell adhesion protein 1; WT, wild type.
Hepatology, Month 2019TARDELLI ET AL.
2
phospholipids or triglycerides (TG) into glycerol and 
fatty acids (FAs),(4,5) with highest expression in the 
brain, white adipose tissue, and liver.(6) In addition, to 
its role in lipid metabolism, MGL is a pivotal compo-
nent of the endocannabinoid system as it hydrolyzes 
2-arachidonoylglycerol (2-AG), an endogenous ligand 
for the cannabinoid receptors, into arachidonic acid 
(AA).(7) Studies in MGL knockout (MGL−/−) mice 
suggested a key role for MGL in metabolic processes 
and energy homeostasis.(8) We previously reported 
that MGL−/− mice fed a high-fat diet gained less 
body weight compared to wild-type (WT) animals.(9) 
Other studies showed that in transgenic mouse mod-
els MGL overexpression in the forebrain resulted 
in a leaner phenotype,(10) whereas overexpression in 
the intestine caused fat accumulation and increased 
food intake.(11) Collectively, these reports depict con-
tradictory roles of MGL in the brain and peripheral 
tissues. Recently, our work investigated the effect of 
MGL deficiency on liver fibrosis development.(12) 
Interestingly, lack of MGL promoted fibrosis regres-
sion due to autophagy-mediated anti-inflammatory 
properties in macrophages.(12) Furthermore, Cao 
et al. showed that global genetic and pharmacolog-
ical inhibition of MGL protects against inflamma-
tion and liver lesions induced by ischemia/reperfusion 
injury.(13) However, the specific role of MGL and its 
metabolites as potential drivers of cholestatic liver dis-
eases such as PBC and PSC is unknown. In the pres-
ent study, we aimed to explore the role of MGL in 
the development of cholangitis and associated com-
plications. By feeding MGL−/− mice a diet containing 
0.1% of 3,5-diethoxycarbonyl-1,4-dihydrocollidine 
(DDC) and treating WT and multidrug resistance 
protein 2 knockout (Mdr2−/−) mice with MGL inhibi-
tor ( JZL184), we analyzed the effects of absent MGL 
activity using these two murine models of PSC. Our 
results indicate that MGL is involved in the devel-
opment of cholestasis and cholangitis as its genetic 
deletion in mice protected from biliary fibrosis and 
inflammation induced by DDC feeding. Notably, 
pharmacological ( JZL184) inhibition of MGL also 
ameliorated DDC-induced cholestasis and protected 
Mdr2−/− mice from spontaneous liver injury improving 
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liver enzymes, inflammation, and biliary fibrosis. 
Further, we report a possible role for MGL and its 
metabolites in the gut–liver axis, where modulation of 
the nuclear receptors (NRs) peroxisome proliferator– 
activated receptor alpha (PPAR-α) and PPAR-γ 
activity by AA diminishes intestinal inflammation 
and prostaglandin E2 (PGE2) content. Overall, our 
results uncover a potential role of MGL inhibition 
in the preservation of liver function and the gut–liver 
axis in cholestatic diseases such as PSC, a disease so 
far lacking effective pharmacological therapy.
Materials and Methods
aNIMal eXpeRIMeNtS
Experiments were performed in 3-month-old 
male MGL−/− mice and WT littermates (C57BL/6J 
background, n = 8 per group unless stated otherwise) 
weighing 25-30 g, generated by R. Zimmermann,(14) 
University of Graz. Mice included in all the experi-
mental setting were littermates bred from a hetero-
zygous colony. All mice were housed in a 12-hour 
light/dark house facility with ad libitum consump-
tion of water and food. They received either a DDC 
diet (A04 chow diet supplemented with 0.1% DDC) 
or standard chow (A04; both from SAFE Diets, 
Augy, France) for 2 weeks. Mdr2−/− mice (FVBN 
background, n  =  9 per group; Jackson Laboratory, 
Bar Harbor, ME) were housed in a 12-hour light/
dark house facility with water and standard chow 
diet (A04) ad libitum. Eight-week-old Mdr2−/− mice 
received either a control diet (A04) or a diet sup-
plemented with 2% of JZL184 (A04  +  JZL184) for 
4 weeks. WT mice received 2 weeks of DDC feed-
ing and 2% of JZL184 or chow for 4 days to inves-
tigate disease resolution. The experimental protocols 
were approved by the local Animal Care and Use 
Committee (BMWF.66.009/0117-II/3b/2013), and 





Livers were fixed in 4% neutral buffered form-
aldehyde solution for 24 hours and embedded in 
paraffin. Sections of 3 μm thickness were stained 
with hematoxylin and eosin (H&E) or sirius red 
as described.(16) For immunohistochemistry (IHC), 
slides were blocked for 60 minutes in blocking buf-
fer (1  ×  phosphate-buffered saline [PBS], 5% goat 
serum and 0.3% Triton X-100).(17) Blocking buffer 
was aspirated, and sections were incubated overnight 
at 4°C with an antimouse osteopontin (OPN) anti-
body (R&D Systems) for OPN detection, vascular 
cell adhesion protein 1 (Vcam-1), and Mac-2 (Santa 
Cruz Biotechnology). Afterward, slides were washed 
3 times in 1 × PBS and incubated for 1 hour at room 
temperature with the respective horseradish perox-
idase–labeled secondary antibody (Dako). Slides 
were then washed and developed with 3-amino-9- 
ethylcarbazole-based or 3,3′-diaminobenzidine-based 
solution and counterstained with hematoxylin. For 
immunofluorescence, slides were incubated with a 
cluster of differentiation 11b (CD11b) peridinin 
chlorophyll protein, cyanine 5.5–labeled antimouse 
(Mac-1α chain, M1/70) (BD Biosciences) and 
counterstained with 4′,6-diamidino-2-phenylindole 
(Sigma). Relative quantification of immunofluores-
cent staining was performed using Image J software 
in an automated fashion.(18)
Cell CUltURe
Caco-2 cells were cultured in Dulbecco’s modi-
fied Eagle’s medium (DMEM) with 4.5 g/L glu-
cose supplemented with 20% fetal bovine serum 
(FBS), L-glutamine (0.2 mol/L), and nonessential 
amino-acids and antibiotics (all Thermo Fisher 
Scientific). Immortalized human hepatocytes 
(IHHs) were cultured in DMEM + 10% FBS, LX2 
cells in DMEM  +  5% FBS, small biliary epithelial 
cells (BECs) in DMEM + 10% FBS, and U937 cells 
in Roswell Park Memorial Institute medium + 10% 
FBS and vitamin D (2.5 ng/mL). After confluence, 
cells were silenced for MGL with Lipofectamine 
2000 Transfection Reagent (Thermo Fisher 
Scientific) and small interfering (si) MGL RNA at a 
concentration of 5 µM (Santa Cruz Biotechnology) 
according to the manufacturer’s instructions. The 
efficiency of transfection was evaluated through 
quantitative RT-PCR and western blot. Thereafter, 
cells were treated with either 100 µM AA or 75 µM 
chenodeoxycholic acid (CDCA) for 6 hours without 
serum.
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lUCIFeRaSe aSSay
Caco2 cells, IHHs, LX2 cells, BECs, and U937 
cells were seeded in a 24-well plate and transiently 
transfected with 0.3 µg/well of the plasmids encod-
ing human farnesoid X receptor (FXR). Human 
(h) PPAR-α, hPPAR-γ, and hRXRα (provided by 
Philippe Lefebvre, Institut Pasteur de Lille, Lille, 
France) and the FXR or PPAR-luciferase (provided 
by Peter Young Dupont, Oakley, CA) using Fugene 
transfection reagent (Promega, Madison, WI) were 
cultured in sterile OptiMeM for 12 hours. Complete 
medium was replaced for an additional 24 hours, 
and cells were lysed using a lysis solution (4% Triton 
X-100, glycyl-glycine 100 mM, MgSO4 100 mM, 
ethylene glycol tetraacetic acid 250 mM) for 1 hour at 
room temperature on a rocking platform. The extracts 
were then combined with solution containing the 
substrate (luciferin 2.5 mM and adenosine triphos-
phate [ATP] 20 mM; Sigma-Aldrich), and luciferase 
activity was measured with a luminometer (Lumat 
LB9507; EG&G Berthold, Germany).
WeSteRN Blot aNalySIS
Tissues were collected in radio immunoprecip-
itation assay buffer, and the protein concentration 
was measured using a 660-nm protein assay kit. 
Protein extracts were processed for crude mem-
brane isolation and loaded on sodium dodecyl sul-
fate–polyacrylamide gel electrophoresis using 10% 
polyacrylamide gels to investigate expression of the 
transporters heme oxygenase 1 protein (HO-1), 
ornithine aminotransferase pseudogene 1 (Oatp1), 
sodium-taurocholate cotransporting polypeptide 
(Ntcp), ATP binding cassette subfamily C mem-
ber 2/3/4 (Mrp2/3/4), bile salt export pump (Bsep), 
MGL (all 1:500; Santa Cruz Biotechnology), and 
calnexin (1:1,000).
gaS CHRoMatogRapHy
Liver and intestine samples (approximately 10 mg) 
were subjected to FA isolation and derivatization. 
All TGs, phospholipids, and cholesterol esters were 
split up into free FAs and derivatized by the methyl 
donor (acidic methanol). A known quantity of C17 
was added to each sample as internal standard. From 
the internal standard, we calculated the values of 
each FA species. After methylation, the sample was 
concentrated in hexane and injected into the gas chro-
matography system.
16S RIBoSoMal RNa 
MICRoBIoMe aNalySIS
Amplicon sequencing of the 16S V3-V4 region 
was performed using MiSeq technology and standard 
Illumina protocols. Sequencing reads were processed 
with deficiency of adenosine deaminase 2 and seven 
in absentia.(19) Statistical analysis was done using R; 
to analyze the similarity of microbial profiles, UniFrac 
and the vegan package adonis were used.(20) The 
Kruskal-Wallis and Wilcoxon (for pairwise compar-
ison) rank sum tests were used to compare bacterial 
abundances.
StatIStICal aNalySIS
All data are expressed as mean ± SD. Statistical 
analyses were performed using the Mann-Whitney 
test with Prism software (GraphPad, CA), unless 
otherwise stated. P ≤ 0.05 was considered statistically 
significant.
For additional methods see Supporting Information.
Results
Mgl DeletIoN atteNUateS 
CHoleStatIC lIVeR aND BIle 
DUCt INJURy INDUCeD By DDC 
FeeDINg
We used the DDC diet as an established model 
to induce sclerosis cholangitis in WT and MGL−/− 
mice. Notably, MGL genetic ablation was protec-
tive against DDC-induced sclerosis cholangitis, as 
shown by diminished serum levels of alanine ami-
notransferase (ALT) and aspartate aminotransfer-
ase (AST), without changes in alkaline phosphatase 
(AP) (Fig. 1A) but (trend-wise) increased serum BAs 
(Supporting Fig. S1A). DDC also increased total 
cholesterol but not TG serum levels in MGL−/− mice 
(Fig. 1B). Furthermore, MGL deletion conserved liver 
architecture in H&E staining (Fig. 1C), diminishing 
ductular reaction and preventing the onion skin–type 
lesions characteristic of sclerosing cholangitis seen in 
WT animals challenged with DDC (Fig. 1C, H&E, 
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WT). Biliary fibrosis was also attenuated as shown 
by sirius red staining (Fig. 1C) and by quantifica-
tion of hepatic hydroxyproline (OH-proline) content 
(Fig. 1D). In line with this, gene expression anal-
ysis revealed a reduction of fibrotic markers such as 
tumor growth factor beta (Tgfβ) and collagen type 1 
α1 and α2 (Col1α1, Col1α2) (Fig. 1E). MGL dele-
tion also improved hepatic Inflammation as reflected 
by the decreased amount of F4/80 gene expres-
sion (Supporting Fig. S1B) and Mac-2 and CD11b 
IHC staining (Fig. 1F; quantification of CD11b 
Supporting Fig. S1C). Proinflammatory markers such 
as monocyte chemoattractant protein 1 (Mcp1) and 
cyclooxygenase-2 (Cox2) were also diminished in the 
liver of DDC-treated MGL−/− compared to WT mice 
(Fig. 1E). Importantly, OPN, Vcam-1, and cytoker-
atin 19 (Ck19), which are markers for proliferative 
bile ducts and reactive cholangiocyte phenotypes, 
were decreased in MGL−/− mice after DDC feeding 
(Fig. 1E,F; Supporting Fig. S1B-D). Altogether, our 
data highlight that MGL deletion protected liver and 
bile ducts from DDC-induced damage.
FIg. 1. MGL−/− mice display reduced biliary fibrosis and inflammation after 2 weeks of DDC feeding. Cholestatic liver injury resembling 
PSC was induced in C57BL/6J and MGL−/− mice (n = 8 per group) by 2 weeks feeding with DDC. (A) Serum biochemistry reflects 
improved levels of transaminases (ALT and AST but unchanged AP) as well as (B) increased cholesterol levels and unchanged TG. 
(C) Representative H&E images (×10 magnification) with markedly improved liver histology and ameliorated fibrosis in line with (D) 
reduced hepatic hydroxy (OH)-proline levels in MGL−/− mice fed DDC. (E) Hepatic gene expression of profibrogenic markers Tgfβ, 
Col1α1, and Col1α2 diminished while proinflammatory cytokines/chemokines Mcp1, Cox2, and Ck19 were reduced after DDC feeding. 
(F) Representative images of Mac-2 and CK19 staining in liver tissue. White/gray bars represent mice fed the control diet; black and 
dashed bars represent mice fed the DDC diet. Results are expressed as mean ± SD. *P < 0.05 for MGL−/− DDC versus WT DDC mice. 
Abbreviations: Ctrl, control; SR, sirius red.
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Next, we investigated the impact of MGL deletion 
on lipid metabolism under baseline and DDC chal-
lenge. Because MGL-deficient mice had higher serum 
levels of cholesterol despite normal TG (Fig. 1B), we 
analyzed key players in lipid and cholesterol metabo-
lism. Notably, cholesterol synthesis was decreased as 
shown by sterol regulatory element-binding protein 
2 (Srebp2), 3-hydroxy-3-methyl-glutaryl-coenzyme 
A reductase (Hmgcr), and low-density lipoprotein 
receptor (Ldlr) gene expression (Fig. 2A). Moreover, 
FA synthesis and uptake increased as reflected by 
Srepb1c, Pparγ2, and its target gene Cd36 (Fig. 2B), 
highlighting an adaptive response to FA/cholesterol 
species within the liver. Pparδ expression remained 
unchanged, but its target gene, Lipin 2, was signifi-
cantly up-regulated (Supporting Fig. S1E). Because 
others have reported mitochondrial dysfunctions 
already after 2 weeks of DDC feeding,(21) we analyzed 
key mitochondrial genes involved in FA oxidation. 
Pparα and its target genes peroxisome proliferator–
activated receptor-gamma coactivator 1 alpha (Pgc1α) 
FIg. 2. MGL deletion down-regulates cholesterol synthesis while increasing FA synthesis and oxidation. (A) Hepatic gene expression 
of Srebp2, Hmgcr, and Ldlr indicates diminished cholesterol synthesis. (B) Hepatic expression of FA synthesis genes increased as seen 
for Srebp1c, Pparγ2, and Cd36 gene. (C) Mitochondrial β-oxidation increased as evidenced by Pparα, Cpt1α, Pgc1α, Aox, and (D) Hmox1 
and Nrf2 gene expression. In line with (E) western blot analysis of HO-1 (calnexin shown as loading control). (F) Hepatic ATP content 
measured in cytosol and mitochondria from liver homogenates increased in MGL−/− DDC. Results are expressed as mean ± SD. *P < 0.05 
for MGL−/− DDC versus WT DDC mice (n = 8). Abbreviation: Ctrl, control.
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and acyl-coenzyme A oxidase (Aox) were up- 
regulated, while carnitine palmitoyltransferase 1A 
(Cpt1α) remained unchanged (Fig. 2C). Interestingly, 
heme oxygenase 1 (Hmox1) gene and protein (HO-
1) expression up-regulated together with the nuclear 
factor erythroid 2–related factor 2 (Nrf2) gene in 
MGL−/− mice (Fig. 2D,E), indicating an antioxidant 
response to DDC intoxication. Moreover, hepatic 
ATP content was increased in cytosol and mitochon-
dria of MGL−/− mice fed DDC, further demonstrating 
a response to compromised oxidative phosphorylation 
by mitochondria (Fig. 2F).
We next addressed whether MGL deletion had an 
impact on BA homeostasis. Notably, cytochrome P450 
7A1 (Cyp7a1) expression was increased (Fig. 3A), and 
BA detoxification was also up-regulated for Cyp3a11 
and in trend for Cyp2b10 (Fig. 3A) in MGL−/− mice 
fed DDC versus WT DDC. In line, DDC treatment 
increased the plasma level of BAs to a higher extent 
in MGL−/− versus WT mice (Supporting Fig. S1A) 
and induced the gene expression of canalicular Mrp2 
in MGL−/− mice (Fig. 3B). Moreover, the basolat-
eral transporters Mrp3 and Mrp4 were increased in 
DDC-fed MGL−/− versus WT mice, while Bsep and 
basolateral Ntcp/Oatp1 remained unchanged (Fig. 3B) 
together with ileal apical sodium-dependent bile acid 
transporter and organic solute transporter alpha/beta 
(Supporting Fig. S1F). Western blot analysis showed 
increased uptake transporters Ntcp/Oatp1, increased 
Mrp2/Mrp4, and decreased Bsep (Fig. 3C,D). 
Collectively, MGL deletion down-regulated choles-
terol synthesis and increased FA uptake/oxidation and 
BA transport while ameliorating mitochondrial dys-
function induced by DDC feeding.
FIg. 3. BA synthesis and export are increased, whereas import is unchanged in MGL−/− mice fed DDC. (A) Hepatic gene expression 
of limiting BA synthesis pathway (Cyp7a1) and detoxification (Cyp3a11, Cyp2b10). (B) Gene expression profiling of Ntcp, Oatp1, Mrp2, 
Mrp3, Mrp4, Bsep. (C) Representative western blot with (D) corresponding densitometry (n = 2 per group) of BA transporters showing 
augmented Mrp2, unchanged secretion (Bsep), and unchanged uptake (Oatp1 and Ntcp), Calnexin was used as a loading control. Results 
are expressed as mean ± SD. *P < 0.05 for MGL−/− DDC versus WT DDC mice (n = 8). Abbreviation: Ctrl, control.
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INteStINal INFlaMMatIoN 
DIMINISHeS IN Mgl−/− MICe 
DeSpIte aa aCCUMUlatIoN
We further aimed to understand whether the 
protective effects in liver seen with MGL inactiva-
tion also affected intestinal homeostasis. Intestinal 
inflammatory markers tumor necrosis factor alpha 
(Tnfα), F4/80, and Cox2 were profoundly decreased 
in MGL−/− mice (Fig. 4A) at the gene expression 
level as well as at the protein level in IHC for Mac-2 
(Supporting Fig. S2A). While gene expression of Pparα, 
Cpt1α, and Pparγ2 (in trend) increased, fibroblast 
growth factor 15 (Fgf15) was diminished (Fig. 4A), 
in line with diminished local inflammation and 
Cyp7a1 induction/increased BA synthesis in the liver. 
In order to understand whether different lipid media-
tors deriving from MGL deletion had a role in intes-
tinal inflammation, we measured the FA content in 
liver and intestine as pivotal ligands for NRs. Notably, 
linoleic acid (18:2w6, in trend) and AA (20:4W6) 
accumulated in the intestine of MGL−/− mice fed the 
DDC diet (Fig. 4B), when no other polysaturated 
or monosaturated FAs accumulated in the intestine 
(not shown). In the liver no significant differences 
were found apart from decreased palmitic acid (16:0) 
in DDC-fed MGL−/− mice (not shown). Because 
AA is converted to the proinflammatory eicosanoid 
PGE2 through COX2, we measured PGE2 content, 
uncovering a decrease in the intestine, liver (in trend) 
(Fig. 4C), and plasma (Supporting Fig. S2B) of 
MGL−/− mice fed DDC versus WT DDC. Because 
other hydrolases are known to convert 2-AG to AA, 
we measured their gene expression, noting an up- 
regulation of α/β hydrolase domains 6 and 12 (Abhd6 
and Abhd12), probably accounting for the increased 
amount of AA despite MGL invalidation (Fig. 4D). 
To investigate the effect of MGL deletion on the 
intestinal microbiome, 16S amplicon sequencing of 
fecal DNA samples was performed. DDC-treated 
FIg. 4. Intestinal inflammation diminishes in MGL−/− mice despite linoleic acid and AA accumulation. (A) Intestinal gene expression 
of proinflammatory genes Tnfα, F4/80, and Cox2 decreased in MGL−/− mice, whereas Pparγ, Pparα, and Cpt1α increased despite Fgf15 
down-regulation. (B) Gas chromatography quantification of intestinal polyunsaturated FAs evidenced accumulation of 18:2w6 (linoleic 
acid) and 20:4w6 (AA) in MGL−/− mice fed DDC (n = 4). (C) PGE2 levels decreased in intestine and liver (trend wise). (D) Intestinal 
gene expression of alternative lipid-hydrolyzing enzymes Abhd6 and Abhd12 were up-regulated in MGL−/− mice fed DDC. (E) DDC 
treated MGL−/− mice showed significantly different microbiome from WT DDC (dot plot) with reduced abundance of Proteobacteria 
(bar graph). Results are expressed as mean ± SD. *P < 0.05 for MGL−/− DDC versus WT DDC mice (n = 8). Abbreviation: Ctrl, control.
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MGL−/− mice showed significantly different microbi-
ome in comparison to DDC-treated WT mice, with 
reduced abundance of Proteobacteria (Fig. 4E).
pHaRMaCologICal BloCKaDe 
oF Mgl ( JZl184) IN Mdr2−/− 
aMelIoRateS BIlIaRy FIBRoSIS 
aND INFlaMMatIoN
We next aimed to verify if MGL pharmacologi-
cal inhibition ameliorates spontaneous cholestasis in 
Mdr2−/−. Mice received 4 weeks of either a chow diet 
or JZL184 treatment. Consistent with our previous 
finding in DDC-fed MGL−/− mice, JZL184 was 
protective in Mdr2−/− as evidenced by diminished 
serum levels of ALT (trend also for AST), AP, BA 
(Fig. 5A,B), nonesterified FAs (Supporting Fig. S3A), 
and H&E (Fig. 5C). Fibrosis was also diminished 
as shown by sirius red staining (Fig. 5C) and by 
quantification of hepatic hydroxyproline content 
(Fig. 5D). Gene expression analysis evidenced dimin-
ished Col1α1, Ck19 (also IHC; Fig. 5F), Vcam-1, 
and Cyp7a1 expression (Fig. 5E) and OPN staining 
(Supporting Fig. S2C). Inflammation was also atten-
uated by MGL inhibition in Mdr2−/−, with decreased 
expression of proinflammatory markers such as Mcp1 
FIg. 5. The MGL inhibitor JZL184 ameliorates biliary fibrosis and inflammation in Mdr2−/− mice. Eight-week-old Mdr2−/− mice were 
fed JZL184 for 4 weeks (n = 9 per group). (A) Serum biochemistry evidenced decreased serum levels of ALT and AP, with unchanged 
AST and (B) diminished plasma BA in JZL184-fed mice but not in Mdr2−/− mice receiving chow. (C) Representative H&E images 
(×10 magnification) with markedly improved liver histology and ameliorated fibrosis (sirius red) confirmed by (D) diminished hepatic 
OH-proline levels. (E) Hepatic gene expression of Col1α1, Cyp7a1, Ck19, and Vcam-1 and proinflammatory cytokine Mcp1 diminished. 
(F) Representative Mac-2 and CK19 IHC pictures show reduced cholangiocyte proliferation and inflammation in JZL184-treated 
Mdr2−/− mice. Results are expressed as mean ± SD. *P < 0.05 for Mdr2−/− in white bars versus Mdr2−/− mice fed JZL184 in black bars and 
WT gray bars. Abbreviation: SR, sirius red.
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(Fig. 5E) and amounts of Mac-2+ (Fig. 5F) and 
CD11b+ (Supporting Fig. S2D) cells in IHC stain-
ing. FAs and cholesterol synthesis remained unaf-
fected as reflected by Srepb1c and Srebp2 expression 
(not shown). Notably, Pparγ1 was down-regulated, 
whereas Pparγ2, Cd36, Pparα, Pgc1α, and Cpt1α 
gene expression was increased in Mdr2−/− mice fed 
JZL184 (Fig. 6A,B). Hmox1 and Nrf2 were up- 
regulated (Fig. 6B), as was hepatic ATP content, in the 
mitochondria of Mdr2−/− mice fed JZL184 (Fig. 6C). 
Intestinal gene expression analysis showed increased 
Pparα, Cpt1α, and Pparγ2 with unchanged Fgf15 
and diminished inflammation as reflected by F4/80 
and Cox2 expression (Fig. 6D) and Mac-2 staining 
(Supporting Fig. S2E). In keeping with our findings 
in MGL−/− mice, AA accumulated in the intestine of 
Mdr2−/− mice fed JZL184 (Fig. 6E), pointing toward a 
potential role of the latter in intestinal inflammation. 
Furthermore, JZL184 induced changes in the micro-
biome composition in Mdr2−/− (Fig. 6F), showing a 
FIg. 6. JZL184 feeding increases hepatic β-oxidation, also leading to diminished inflammation in the intestine. (A) Gene expression of 
Pparγ1, Pparγ2, and Cd36 and (B) Pparα, Cpt1α, Pgc1α (in trend), Hmox1, and Nrf2 (in trend) is up-regulated. (C) Hepatic ATP content 
increased in mitochondria but not in cytosol. (D) Intestinal gene expression of Pparα and Cpt1α is up-regulated, whereas Pparγ2 and 
Fgf15 remained unchanged; inflammatory markers F4/80 and Cox2 are strongly decreased. (E) Gas chromatography quantification of 
polyunsaturated FAs in the intestine from Mdr2 −/− mice fed JZL184 evidenced enrichment of AA. (F) Microbiome analysis showed 
changed microbial composition in Mdr2−/− mice fed JZL184, with reduced abundance of Ruminococcaceae compared to Mdr2 WT. 
Results are expressed as mean ± SD. *P < 0.05 for Mdr2−/− versus Mdr2−/− JZL184-fed mice (n = 9). Abbreviation: NMDS, nonmetric 
multidimensional scaling.
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reduced abundance of Ruminococcaceae compared 
to WT. Hepatobiliary bile flow, biliary HCO3– out-
put, and biliary BA output remained unremark-
able in mice fed JZL184 (Supporting Fig. S3B,C). 
Importantly, protein expression of BA transport-
ers showed increased uptake (Ntcp) and canalicular 
export capacity (Bsep/Mrp2) and unchanged baso-
lateral export (Mrp3/4) (Supporting Fig. S3D,E) in 
Mdr2−/− mice fed JZL184 (in line with the decreased 
plasma BA). Altogether, our data confirm the protec-
tive effect of MGL inhibition in a second model of 
cholestasis liver injury.
Mgl INHIBItoRS MItIgateS 
CHoleStatIC INJURy aFteR DDC 
CHalleNge
In order to evaluate whether pharmacological 
inhibition of MGL accelerates regression of choles-
tatic liver injury after DDC feeding, we fed WT 
mice the DDC diet for 2 weeks and analyzed disease 
regression after 4 days of either chow or JZL184 
treatment. Liver transaminases showed a signif-
icant decrease in AST and a trend for ALT with 
unchanged AP (Fig. 7A), while plasma bilirubin was 
FIg. 7. The MGL inhibitor JZL184 mitigates cholestatic injury after DDC feeding. WT mice received 2 weeks of DDC feeding and 
4 days of JZL184 to investigate disease resolution. (A) Serum biochemistry reflects diminished levels of serum transaminases (ALT 
and trend for AST but unchanged AP) and (B) bilirubin. (C) Representative H&E images (×10 magnification) with improved liver 
histology and ameliorated fibrosis (sirius red) in WT animals fed DDC+JZL184. (D) Hepatic gene expression of profibrogenic markers 
Tgfβ and Col1α1 diminished, while proinflammatory cytokines/chemokines Mcp1 and Cox2 remained unchanged and Ck19 diminished. 
(E) Hepatic gene expression of Srebp1c and Srebp2 was unchanged, Fasn diminished, whereas Aox and Pparα increased. (F) Representative 
images of Mac-2 and CK19 staining in liver tissue showing ameliorated inflammation and cholangiocyte reactive phenotype. Gray bars 
represent control mice fed chow; white bars represent DDC + chow diet; black bars represent mice fed the DDC + JZL184 diet. Results 
are expressed as mean ± SD. *P < 0.05 for WT DDC + chow versus DDC + JZL184. Abbreviations: Ctrl, control; SR, sirius red.
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significantly reduced in the JZL184-fed group ver-
sus the group fed chow (Fig. 7B); TG and choles-
terol levels remained unchanged (not shown). IHC 
staining showed diminished ductular reaction for 
H&E and decreased fibrosis on sirius red staining 
(Fig. 7C). Expression analysis of proinflammatory 
and profibrogenic genes showed decreased Col1a1, 
Tgfb, Mcp1, and Ck19 and unchanged Cox2 (Fig. 7D). 
Lipid metabolic genes decreased for Srebp1c and FA 
synthase (Fasn) and increased for Aox and Pparα, 
whereas Srebp2 remained unchanged (Fig. 7E). 
Notably, Mac-2 and CK19 staining intensity was 
reduced in mice receiving JZL184 after the DDC 
diet (Fig. 7F). Altogether, these results suggest that 
MGL inhibition could mitigate liver injury after 
DDC challenge.
SIleNCINg Mgl Up-RegUlateS 
ppaR-α aND ppaR-γ ReSUltINg 
IN DIMINISHeD INteStINal 
INFlaMMatIoN
To further explore the molecular mechanism, we 
silenced MGL with siRNA in human Caco-2 cells 
(Fig. 8A). When MGL was silenced, gene expression 
of the NRs Pparγ, Pparα, and target gene Cpt1α was 
up-regulated, while Fxr was down-regulated with 
a similar trend for Fgf19 (Fig. 8B). FXR agonism 
by CDCA was blunted after siMGL in Caco-2 as 
demonstrated by reduced Fxr and downstream tar-
gets such as Fgf19, small heterodimer protein, ileal 
BA binding protein, and gel shift assay (Supporting 
Fig. S4A,B). For IHHs, Fgf19 and Fxr were dimin-
ished, for cholangiocytes (BECs) only Fxr was dimin-
ished, while no changes were seen for hepatic stellate 
cells (LX2) and macrophages (U937) (Supporting 
Fig. S4A). Caco-2 cells treated with AA showed 
diminished inflammation as evidenced by Tnfα and 
Cox2 (trend) gene expression (Fig. 7C). Retinoid X 
receptor alpha (RXRα; NR2B1), a member of the 
NR superfamily, is a promiscuous heterodimeric part-
ner for many NRs, including PPARs and FXR.(22) A 
transfection assay with PPAR-α, PPAR-γ, and RXR 
on their response element demonstrated up-regulation 
of their respective luciferase activity after treatment 
with AA (Fig. 8D), accumulating in the intestine 
after MGL deletion/inhibition (Figs. 4B and 6E). In 
other liver cell types peroxisome proliferator–response 
element (PPRE) luciferase activity was up-regulated 
after AA treatment for PPAR-α only in IHHs and 
PPAR-γ in LX2 cells, whereas BECs and U937 cells 
were unresponsive (Supporting Fig. S4C). In addition, 
the FXR/RXR heterodimer binds to FXR response 
elements (FXREs), which in turn control the response 
to BAs. RXRα is also able to bind to FAs such as 
docosahexaenoic acid and AA.(23) Because RXR is the 
heterodimeric partner of FXR, we tested whether AA 
would disrupt FXR signaling in the intestine. Indeed, 
we demonstrate that RXR agonism induced by AA in 
turn antagonizes ligand-bound FXR-induced expres-
sion of FXRE luciferase activity (Fig. 8E). Altogether, 
these data demonstrate that MGL deletion favors 
the accumulation of AA in the intestine, triggering 
protective mechanisms through NR activation coun-
teracting cholestatic liver disease progression, as sum-
marized in Fig. 8F.
Discussion
Cholestatic liver diseases are characterized by 
impaired bile formation, resulting in hepatic accu-
mulation of BA, cholesterol, and bilirubin(24); once 
BAs accumulate in high concentrations, they can leak 
from canaliculi and bile ducts, thus causing hepatic 
cell death, inflammation, fibrosis, and cancer.(25) 
Cholestatic liver diseases are also known to impair the 
intestinal absorption of FAs and sterols due to poor 
micellar formation secondary to reduced bile forma-
tion and excretion.(26) An important feature of PSC 
is its association with inflammatory bowel disease and 
ulcerative colitis.(27) In fact, a leaky gut allows bacterial 
products to reach the liver and cause inflammation, 
making the gut–liver axis a pivotal player in disease 
pathogenesis.(27) We hypothesized that MGL inval-
idation may represent an attractive target by modu-
lating FA and BA metabolism as well as providing 
ligands for NRs in the liver and intestine, ultimately 
driving protective mechanisms to counteract biliary 
injury and fibrosis. While previous reports evidenced 
the pivotal role of MGL in tumor growth, in metab-
olism,(28) in oncogenic signaling such as invasion 
and migration,(28) and as a prognostic indicator for 
hepatocellular carcinoma,(29) others have shown that 
MGL deletion resulted into colorectal cancer growth 
inhibition,(30) also attenuating acute lung injury in 
mice(31) and improving adipose tissue inflammation 
and insulin resistance in obese mice.(8) In addition, 
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we recently showed that MGL invalidation strongly 
decreases fibrogenesis due to autophagy-mediated 
anti-inflammatory properties.(12) However, very little 
is known about the role of MGL in cholestatic dis-
eases including PSC, a cholangiopathy with the 
largest unmet medical need due to lack of effective 
FIg. 8. Silencing MGL in intestinal cells up-regulates PPAR-α and PPAR-γ in vitro, and AA binds PPARs/RXR, diminishing 
inflammation. MGL was silenced in Caco2 cells. (A) Representative western blot with corresponding Image J quantification showing 
successful silencing at 5 µM concentration. (B) Caco2 siMGL had induction of Pparγ, Pparα, and Cpt1α with unchanged Fgf19 gene 
expression and decreased Fxr. (C) Gene expression of proinflammatory genes Tnfα and Cox2 down-regulated after treatment with AA in 
siMGL Caco2 cells. (D) Transfection of PPARα, PPARγ, and RXR showed increased luciferase activity of PPRE after AA incubation. 
(E) Cotransfection of RXR/FXR shows that AA antagonizes induction of FXRE by CDCA. Results are expressed as mean ± SD of three 
independent experiments in duplicate, *P < 0.05 for siMGL versus siMGL+CDCA and AA treatment versus control or CDCA+AA 
treatment versus CDCA alone. (F) MGL deletion ameliorates cholestatic liver disease induced by DDC challenge diminishing fibrosis, 
inflammation, and FA metabolism/oxidation in the liver. It also induces BA synthesis and detoxification as shown by Cyp7a1/Cyp3a11 
induction and BA transport (Mrp4) with unchanged Bsep and increased Mrp2. In the intestine, accumulation of AA binds NRs PPAR-α, 
PPAR-γ, and RXRα, resulting in anti-inflammatory effects as further demonstrated by diminished PGE2 content. Abbreviations: Chol, 
cholesterol; Ctrl, control; βox, β-oxidase.
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pharmacological therapies.(3) To address this ques-
tion, we challenged MGL−/− mice with acute DDC 
feeding for 2 weeks, discovering that MGL deletion 
decreases ductular reaction with diminished reactive 
cholangiocyte phenotype, fibrosis, and inflammation. 
FA synthesis and uptake were up-regulated, coupled 
with increased mitochondrial β-oxidation, suggest-
ing a futile circle of hydrolysis and esterification in 
the liver. BA transport was increased, thus explain-
ing the relatively increased amount of plasma BAs 
in MGL−/− mice fed DDC, although Mdr2−/− mice 
showed decreased BA. This suggests that bile duct 
injury may be improved without affecting cholestasis/
BA homeostasis. Importantly, ileal inflammation was 
diminished due to increased PPAR-α and PPAR-γ in 
DDC-treated MGL−/− mice; a more detailed analysis 
of molecular FA species revealed enrichment of the 
AA intestinal pool in MGL−/− mice due to increased 
expression of alternative lipid-hydrolyzing enzymes 
Abhd6 and Abhd12. In addition, we explored the rel-
evance of our findings in a therapeutic setting, treating 
Mdr2−/− mice (an established model of PSC developing 
spontaneous sclerosing cholangitis and biliary fibro-
sis), with the MGL inhibitor JZL184. Importantly, 
MGL inhibition confirmed the protective effects in 
Mdr2−/− mice, which showed reduced biliary fibro-
sis and inflammation. FAs and cholesterol synthe-
sis remained unaffected, while FAs and β-oxidation 
improved in JZL184-treated mice. Intriguingly, gas 
chromatographic analysis of FA species revealed 
AA accumulation in the intestine with diminished 
inflammation and NR up-regulation after 4 weeks of 
JZL184 feeding. Gut microbiome analysis evidenced 
reduced abundance of Proteobacteria in MGL−/− mice 
fed DDC, which are known to be overexpressed in 
inflammatory conditions; and children with nonalco-
holic steatohepatitis have shown gradual increase in 
Proteobacteria in comparison to healthy controls.(32,33) 
In Mdr2−/− mice, Ruminococcaceae—positively cor-
related with the production of beneficial short-chain 
FAs and AA,(34) which show anti-inflammatory prop-
erties in the intestine—were restored by JZL184 feed-
ing to levels comparable to WT mice.
In WT mice, cholestatic liver injury was mitigated 
by JZL184 treatment after 2 weeks of DDC feeding. 
Intriguingly, the different plasma BA response to injury 
in the MGL−/− DDC and Mdr2−/− models could be 
linked to the etiopathogenesis of cholestatic liver injury 
because Mdr2−/− mice are known to develop cholestasis 
from toxic biliary BA composition, while DDC rep-
resents a more direct xenobiotic induced form of bile 
duct injury. Mechanistically, in vitro experiments 
provided compelling evidence that MGL silencing 
leads to PPAR-α and PPAR-γ up-regulation, while 
AA binds PPAR-α, PPAR-γ, and RXR in luciferase 
assay, also inducing antagonism of FXR activity. This 
is in line with a previous report demonstrating that 
RXR agonism induces respective antagonism of FXR 
activity due to absence of coactivator recruitment and 
decreased DNA binding.(35) NRs are known actors 
in PSC and PBC; PPARα is, for instance, involved 
in BA homeostasis, repressing its synthesis through 
hepatocyte nuclear factor 4 alpha, which binds to the 
Cyp7a1 promoter.(36) PPARα ligands such as fibrates 
repress BA synthesis and promote phospholipid 
secretion into bile through induction of Mdr3.(37) 
PPARγ instead is an important target for inflamma-
tory cholestasis because of its crucial role in attenu-
ating inflammation. In a lipopolysaccharide (LPS) 
model of inflammatory cholestasis, treatment with 
glitazones was shown to attenuate the repression of 
Ntcp, Bsep, and Cyp3a11.(38) Finally, RXR was shown 
to modulate inflammation in acute colitis,(39) whereas 
FXR activation was demonstrated to limit hepatic 
inflammation by inhibiting the nuclear factor kappa 
Β–mediated inflammatory response,(40) also restricting 
fibrosis.(41) Although current strategies in cholesta-
sis favor FXR agonists,(42) FXR antagonism was also 
found to be beneficial in obesity and insulin resis-
tance through gut–liver axis involvement and micro-
biome modulation.(43) Moreover, mice lacking FXR 
are protected from cholestatic injury due to adaptive 
induction of alternative (FXR-independent) detoxifi-
cation pathways regulated by pregnane X receptor and 
constitutive androstane receptor.(44,45) A key relevant 
finding of this study is that MGL products amelio-
rate intestinal inflammation through NR signaling 
and AA binding, and this might be of great relevance 
in the context of intestinal disorders connected to 
cholestatic diseases. COX-2 oxidizes 2-AG to gen-
erate prostaglandin glycerol esters (PG-G) through 
pathways closely matching those of the respective 
prostaglandins formed from AA.(46) Importantly, it 
has been demonstrated that, under specific condi-
tions, 2-AG-derived PG-G species are formed by 
COX-2 action and that these metabolites likely have 
bioactivities of their own, mediated through as yet 
unknown nonprostaglandin receptors.(47) For instance, 
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pharmacologic inhibition of Abhd6 in an LPS murine 
model induced 2-AG accumulation in macrophages 
and channeling to COX-2-derived anti-inflammatory 
PG-G species, including PGD2-G, a precursor of 
15d-PGJ2-G.(48) Moreover, in vivo administration of 
PGD2-G was shown to reduce LPS-induced inflam-
mation.(48) Another study revealed that Abhd6 hydro-
lyzes PGD2-G, whereas MGL prefers 15d-PGJ2-G, 
which in turn activates the Nrf2 signaling pathway, 
in line with our data in the liver.(49) In light of our 
findings, AA accumulation might not only channel 
PGD2-G generation but could also concomitantly 
result in an anti-inflammatory effect due to direct 
binding to NRs. This should be a viable hypothesis to 
be tested in future in vivo studies.
In summary, we demonstrate that MGL dele-
tion has crucial roles in the regulation of lipid and 
BA homeostasis, rescuing mitochondrial respiration/ 
antioxidant response and ameliorating cholestatic dis-
ease. Intestinal inflammation was positively affected by 
lipid signaling, microbial changes, and AA accumulation 
in both animal models, pointing to a shared molecular 
mechanism which involved RXR binding, activation of 
PPARs, and FXR competition.(50) Therefore, our find-
ings may open therapeutic horizons in treating choles-
tatic liver diseases such as PSC through the gut–liver 
axis, suggesting the potential for selective MGL antag-
onists as a future treatment strategy.
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